查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1933849

胃部空間佔用裝置市場（按產品類型、給藥途徑、安裝週期、最終用戶和分銷管道分類），全球預測，2026-2032年

Gastric Space-Occupying Device Market by Product Type, Route Of Administration, Duration Of Placement, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年胃定位裝置市值為 3.2582 億美元，預計到 2026 年將成長至 3.6311 億美元，預計到 2032 年將達到 8.1045 億美元，複合年成長率為 13.90%。

關鍵市場統計數據
基準年 2025 3.2582億美元
預計年份：2026年 3.6311億美元
預測年份 2032 8.1045億美元
複合年成長率 (%) 13.90%

本文全面介紹了臨床需求、醫療設備創新和不斷變化的照護流程如何重塑醫療器材的採納和策略重點。

當侵入性手術並非首選或迫在眉睫的治療方案時，胃佔位裝置正日益被視為肥胖和代謝性疾病綜合治療策略的重要組成部分。這些裝置旨在減少胃容量並改變飽腹感訊號，在藥物治療和減重手術之間佔據著獨特的臨床定位，推動了內視鏡室、門診中心和專科診所等多種診療模式的創新。與侵入性更強的治療方案相比，這些裝置具有可逆性、可調控的治療方案以及更低的手術全期併發症，因此更受臨床醫生的青睞，這也影響著市場需求和臨床應用模式。

對正在重新定義醫療器材設計和醫療服務路徑的技術、臨床、監管和病患偏好趨勢進行策略分析

由於裝置設計、輸送技術和以患者為中心的護理模式的同步進步，胃內裝置領域正經歷著變革性的轉變。設計人員不斷改進裝置幾何形狀，包括可調節機制和混合液氣結構，以提高耐受性和治療控制。同時，可吞嚥裝置憑藉其微創的輸送方式，正挑戰內視鏡置入的優勢。這些技術變革也伴隨著手術流程從醫院向門診手術中心和專科診所的轉移，從而為降低成本、加快患者周轉率和擴大地域覆蓋創造了機會。

本文檢驗不斷變化的關稅政策如何重塑醫療設備供應鏈的採購、製造決策和商業性韌性。

美國新關稅政策的實施對依賴一體化國際供應鏈的醫療設備製造商、供應商和下游醫療服務提供者產生了重大影響。關稅調整增加了從海外採購的零件和組件的投入成本，可能擠壓製造商的利潤空間，並促使其在競爭激烈的競標環境中進行價格調整。更重要的是，關稅也在改變策略採購決策，促使供應商和製造商重新檢視供應商合約、探索近岸外包方案或整合採購量以降低關稅風險。

一份詳細的細分分析報告，闡述了產品形態、護理環境、交付管道、分銷模式和安裝週期如何相互作用，從而影響商業化策略。

分析這種細分市場的細微差別，可以發現影響產品設計、市場推廣策略和臨床定位的許多因素。依產品類型分析，可調式裝置、雙液/氣配置、單液填充式和單氣填充式裝置之間的差異，造就了不同的臨床應用情境。可調式裝置提供漸進式治療控制，適合需要個人化治療的患者，而單液或單氣填充式裝置則可能優先考慮操作簡單性和降低裝置複雜性。這些產品層面的差異會波及臨床訓練需求、裝置使用壽命考量以及病患諮詢通訊協定。

分析監管、報銷和臨床基礎設施方面的區域差異，以確定區域引進路徑和市場進入策略。

區域趨勢反映了美洲、歐洲、中東和非洲以及亞太地區在法規結構、臨床基礎設施、支付方優先事項和患者人口結構方面的差異。在美洲，成熟的內視鏡網路、高普及率的專業減重手術計畫以及日益認可微創手術的報銷環境，為先進器械的研發和長期療效研究創造了有利條件。儘管商業化路徑可能較為複雜，但成熟的臨床試驗網路和集中式卓越中心能夠加速實證醫學證據的產生和推廣​​應用。

公司策略行動和競爭優勢，展現了產品藍圖、證據規劃和供應鏈敏捷性如何創造永續優勢。

該領域的領導企業透過互補策略脫穎而出，這些策略融合了產品創新、實證實踐和策略夥伴關係。成功的公司傾向於投資模組化產品路線圖，以便在保持藍圖連續性的同時，逐步改進產品，例如最佳化給藥系統、增強可調控制功能和整合監測。這種方法縮短了迭代升級的上市時間，並能夠建立更有針對性的臨床醫生回饋機制，從而最佳化使用者體驗。

這是一份實用指南，旨在協調產品開發、臨床證據、供應鏈韌性和市場進入，從而推動創新並實現規模化應用。

產業領導者應優先進行一系列協作，協調工程、臨床、商業和監管職能，以加速產品推廣應用並降低市場風險。首先，將實證策略融入產品開發，結合臨床終點、病患報告結局和衛生經濟學終點，向支付者和醫療服務提供者證明產品價值。其次，推行模組化工程，以支援可擴展的混合產品變體，同時最大限度地減少增量更新帶來的監管負擔。

我們採用透明、多方面的研究途徑，結合臨床醫師訪談、文獻綜述、監管圖譜和技術格局分析，以指導策略選擇。

本分析整合了多種調查方法，以確保其穩健性和對策略決策的相關性。主要研究包括對臨床醫生、採購人員和醫療設備開發人員進行結構化訪談，以收集關於手術流程、器械偏好和臨床證據期望的真實世界觀點。次要研究包括對同行評審的臨床文獻、監管指導文件和已發布的手術操作指南進行系統性回顧，以根據目前的臨床標準和安全考慮得出研究結果。

綜合分析總結表明，臨床創新、營運準備和報銷策略必須保持一致，才能確保持續的商業成功。

累積的證據表明，胃部佔位裝置正處於一個轉折點。技術創新、醫療服務模式的變革以及支付方的期望相互交織，既帶來了機遇，也帶來了挑戰。具備可調控制、操作簡便、安全性明確的裝置最能滿足臨床醫師和病患的需求，而能夠減輕手術負擔的給藥途徑則有助於擴大病患群體。同時，區域監管差異以及關稅帶來的供應鏈壓力，要求制定周密的策略規劃，以避免執行過程中出現失誤。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依產品類型分類的胃腔佔位裝置市場

  • 可調節的
  • 兩種液體和氣體類型
  • 單液填充型
  • 單氣填充型

9. 依給藥途徑分類的胃腔佔位裝置市場

  • 內視鏡
  • 口服型

10. 依留置時間分類的胃腔佔位裝置市場

  • 長期
  • 短期

11. 依最終用戶分類的胃腔佔位裝置市場

  • 門診手術中心
  • 肥胖治療診所
  • 醫院

12. 依分銷管道分類的胃腔佔位裝置市場

  • 直銷
  • 經銷商

第13章 胃腔佔位裝置市場：依地區分類

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

14. 胃腔佔位裝置市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國胃腔佔位裝置市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國胃部空間佔用裝置市場

第17章 中國胃佔位裝置市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Allurion Technologies, Inc.
  • Apollo Endosurgery, Inc.
  • BaroNova Therapeutics
  • Districlass Medical
  • Endalis
  • Endogastric Solutions
  • Fengh Medical
  • G-Surgery
  • Helioscopie Medical Implants
  • Lexel Medical
  • Life Partners Europe
  • Medicone
  • Medsil
  • Obalon Therapeutics, Inc.
  • Phagia Technologies
  • ReShape Lifesciences Inc.
  • Silimed
  • Silimed Ltda
  • Spatz Medical Ltd.
  • Tulip Medical
Product Code: MRR-C36616F6997F

The Gastric Space-Occupying Device Market was valued at USD 325.82 million in 2025 and is projected to grow to USD 363.11 million in 2026, with a CAGR of 13.90%, reaching USD 810.45 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 325.82 million
Estimated Year [2026] USD 363.11 million
Forecast Year [2032] USD 810.45 million
CAGR (%) 13.90%

Comprehensive introduction outlining how clinical needs, device innovations, and care pathway shifts are reshaping adoption and strategic priorities

Gastric space-occupying devices are increasingly recognized as a component of multidisciplinary strategies for managing obesity and metabolic disease where invasive surgery may not be the immediate or preferred option. These devices, designed to reduce gastric volume and alter satiety signaling, occupy a distinct clinical niche between pharmacotherapy and bariatric surgery and are driving new care pathways across endoscopy suites, ambulatory centers, and specialized clinics. Clinicians are attracted to options that offer reversible effects, adjustable therapeutic profiles, and reduced peri-procedural morbidity relative to more invasive alternatives, which in turn shapes demand and clinical adoption patterns.

From a development perspective, innovation is converging on device ergonomics, delivery mechanisms, and materials that optimize patient comfort, ease of implantation and removal, and durability for intended durations of placement. Parallel advances in procedural practice and training-particularly in endoscopic techniques-have reduced procedural variability and expanded the cohort of physicians able to offer these therapies. As a result, payers, providers, and manufacturers are re-evaluating pathways to evidence generation, long-term follow-up, and value demonstration to ensure these devices align with evolving standards of care and reimbursement criteria.

Taken together, the introduction of new device formats and the migration of procedures into lower-acuity settings are reshaping clinical workflows and commercial strategies. Stakeholders should consider how clinical evidence, user experience, and cost-efficiency will jointly determine the trajectory of adoption in the coming years.

Strategic analysis of converging technological, clinical, regulatory, and patient preference trends that are redefining device design and care delivery pathways

The gastric device landscape is undergoing transformative shifts driven by simultaneous advances in device design, delivery techniques, and patient-centered care models. Designers are iterating on form factors that include adjustable mechanisms and hybrid fluid-gas constructs to improve tolerability and therapeutic control, while swallowable devices are challenging the primacy of endoscopic placement by offering less invasive administration. These technical shifts are complemented by procedural migration from hospitals to ambulatory surgical centers and specialized clinics, creating opportunities for cost reduction, faster patient throughput, and broader geographic access.

Regulatory trends are also influencing strategic decisions. Regulators are increasingly emphasizing robust post-market surveillance and real-world evidence to support claims, encouraging manufacturers to integrate monitoring and data capture capabilities into device ecosystems. Payer requirements are evolving toward outcomes-based reimbursement models in which long-term effectiveness and safety evidence will be critical. Concurrently, patient expectations now favor minimally disruptive interventions that fit into outpatient workflows and deliver measurable improvements in quality of life, which has heightened the focus on device comfort, ease of use, and reversible options.

Collectively, these forces are prompting manufacturers to pursue differentiated clinical programs, modular product portfolios, and partnerships that accelerate access to lower-acuity settings. Companies that align engineering innovation with evidence generation and clear reimbursement pathways will be best positioned to capitalize on the shift toward less invasive obesity management solutions.

Focused examination of how evolving tariff policies are reshaping sourcing, manufacturing decisions, and commercial resilience across the device supply chain

The introduction of new tariff policies in the United States has created material implications for device manufacturers, suppliers, and downstream providers that rely on integrated international supply chains. Tariff adjustments raise input costs for components and subassemblies sourced from overseas, which can compress manufacturer margins or prompt price adjustments that are sensitive in competitive procurements and tender environments. Importantly, tariffs also alter strategic sourcing calculus, incentivizing suppliers and manufacturers to reassess vendor contracts, explore nearshoring options, or consolidate purchasing volumes to mitigate customs exposure.

Manufacturers facing increased landed costs must weigh responses that include absorption of cost increases, selective price increases, or engineering redesigns to source alternative materials. Each option carries trade-offs: absorbing costs affects profitability and potential reinvestment in clinical programs; price increases may reduce competitiveness in payor negotiations and procurement cycles; redesigns require time and regulatory clarity to avoid disruptions. Moreover, device companies with vertically integrated manufacturing outside tariff jurisdictions may gain short-term advantages, while pure-play importers may encounter margin pressure and inventory valuation impacts.

Beyond direct cost effects, tariffs influence investment decisions around capacity expansion, contract manufacturing relationships, and inventory strategies. Firms may pursue diversified supplier networks and inventory pre-positioning to maintain service levels, while others may accelerate localization of production to preserve pricing flexibility. Ultimately, organizations that proactively model tariff scenarios, adjust procurement strategies, and communicate transparently with clinical and commercial partners will be better positioned to navigate the cumulative effects on supply continuity and competitive dynamics.

In-depth segmentation insights explaining how product form, care setting, delivery route, distribution model, and placement duration interact to shape commercialization strategies

A nuanced view of segmentation reveals multiple vectors that inform product design, go-to-market strategy, and clinical positioning. When analyzed by product type, distinctions among adjustable devices, dual fluid-gas constructions, single fluid-filled formats, and single gas-filled options drive divergent clinical use cases; adjustable devices offer titratable therapeutic control suited to patients requiring individualized therapy, while single fluid or gas-filled designs may prioritize procedural simplicity and lower device complexity. These product-level differences cascade into clinical training needs, device lifespan considerations, and patient counseling protocols.

End-user segmentation between ambulatory surgical centers, bariatric clinics, and hospitals affects procurement cycles, capital equipment considerations, and procedural throughput expectations. Ambulatory surgical centers frequently emphasize efficiency and day-case recovery, making compact delivery systems and short procedure durations especially valuable, whereas hospitals may prioritize integration with complex comorbidity management programs. Route of administration divides the market into endoscopic and swallowable solutions, each with distinct clinical pathways, risk profiles, and practitioner skill sets; swallowable devices expand access by minimizing procedural sedation, while endoscopic devices allow direct visualization and retrieval control.

Distribution channel choices between direct sales and distributor partnerships influence market reach and service expectations. Direct sales models can facilitate closer clinical training and data collection but require investment in field resources, whereas distributor relationships can accelerate geographic penetration with lower fixed costs. Duration of placement, whether long-term or short-term, affects follow-up scheduling, surveillance protocols, and outcome metrics, demanding clear labeling, patient education, and evidence tailored to each intended use horizon. Integrating these segmentation layers into product and commercial planning yields strategies that align clinical utility with distribution and reimbursement realities.

Cross-regional analysis of regulatory, reimbursement, and clinical infrastructure differences that determine localized adoption pathways and market access tactics

Regional dynamics reflect differences in regulatory frameworks, clinical infrastructure, payer priorities, and patient demographics across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. In the Americas, established endoscopy networks, a high prevalence of specialized bariatric programs, and a reimbursement environment that increasingly recognizes minimally invasive interventions create fertile conditions for advanced device formats and long-term outcome studies. While commercialization pathways may be complex, the maturity of clinical trial networks and centralized centers of excellence can accelerate evidence generation and adoption.

Europe, Middle East & Africa presents heterogeneous regulatory pathways and payer landscapes that require localized market access strategies. Countries with centralized health technology assessments emphasize cost-effectiveness and long-term outcomes, prompting manufacturers to develop region-specific clinical dossiers and engage early with payers. The Middle East and parts of Africa show growing interest in minimally invasive obesity interventions, driven by rising obesity prevalence and investments in specialty care, but uptake is contingent on training and infrastructure development.

Asia-Pacific includes markets with rapidly expanding endoscopy capacity, variable reimbursement structures, and distinct patient and clinician preferences that favor less invasive, cost-efficient options. Several markets within the region prioritize domestic manufacturing and regulatory pathways that emphasize local data, which can affect market entry sequencing. Overall, regional approaches must balance global evidence packages with local clinical, regulatory, and commercial adaptation to drive sustainable adoption.

Corporate strategic behaviors and competitive differentiators demonstrating how product roadmaps, evidence programs, and supply chain agility create sustainable advantages

Leading organizations in the space are differentiating through complementary strategies that combine product innovation, evidence generation, and strategic partnerships. Successful actors tend to invest in modular product roadmaps that allow incremental improvements-such as enhanced delivery systems, adjustable controls, and integrated monitoring-while preserving regulatory continuity. This approach reduces time to market for iterative upgrades and enables more targeted clinician feedback loops to refine user experience.

Clinical differentiation is frequently achieved through robust investigator-initiated studies, registry development, and long-term surveillance programs that substantiate safety and functional outcomes. Companies that prioritize prospective, real-world evidence collection gain stronger positioning with payers and providers seeking long-term performance data. In parallel, strategic commercial alliances with procedure service providers, training networks, and diagnostic partners extend reach into ambulatory and specialized clinic settings and enable bundled care models.

Manufacturing and supply chain strategies are also pivotal. Firms leveraging flexible contract manufacturing, localized assembly, or dual-sourcing can maintain supply continuity while controlling costs. Finally, those that align reimbursement and health economics teams early in development to craft payer narratives and value dossiers tend to achieve smoother access and uptake. Collectively, these company-level choices define competitive separation between product-centric players and integrated solutions providers.

Actionable playbook for aligning product development, clinical evidence, supply chain resilience, and market access to translate innovation into scalable adoption

Industry leaders should prioritize a coordinated set of actions that align engineering, clinical, commercial, and regulatory functions to accelerate adoption and mitigate market risk. First, integrate evidence strategy with product development by pairing clinical endpoints with patient-reported outcomes and health economic endpoints so that value is demonstrable to payers and providers. Second, pursue modular engineering that supports adjustable and hybrid product variants while minimizing regulatory burden for incremental updates.

Third, strengthen supply chain resilience by diversifying suppliers, evaluating nearshore manufacturing options, and developing inventory contingency plans to reduce exposure to trade policy volatility. Fourth, design go-to-market approaches that reflect heterogeneity in end users: tailor training and service models for ambulatory surgical centers and bariatric clinics while maintaining hospital-focused pathways for complex cases. Fifth, engage early with payers and HTA bodies to co-develop evidence requirements and reimbursement pathways, thereby reducing friction during commercial launch.

Finally, consider partnerships with clinical networks and diagnostic providers to bundle care solutions that simplify procurement and create measurable care pathways. Executing on these priorities requires governance mechanisms that ensure cross-functional accountability, timely decision-making, and iterative learning from post-market data. Organizations that adopt this integrated playbook will better convert technological advances into sustainable clinical and commercial outcomes.

Transparent and multi-method research approach combining clinician interviews, literature synthesis, regulatory mapping, and technical landscape analysis to inform strategic choices

This analysis synthesizes multiple methodological approaches to ensure robustness and relevance for strategic decision-making. Primary research included structured interviews with clinicians, procurement leaders, and device innovators to capture frontline perspectives on procedural workflows, device preferences, and clinical evidence expectations. Secondary research entailed a systematic review of peer-reviewed clinical literature, regulatory guidance documents, and published procedural practice guidelines to ground insights in contemporary clinical standards and safety considerations.

The research also incorporated a comparative regulatory analysis across key jurisdictions to map approval pathways, post-market surveillance requirements, and emerging payer expectations. Device design trends were assessed through technical literature and patent landscape scans to identify recurring innovation themes and potential blueprints for differentiation. To validate findings, triangulation was performed by cross-referencing interview insights with clinical registry data and public filings where available, ensuring consistency between practitioner-reported experiences and documented outcomes.

Finally, data quality controls included source validation, expert review cycles, and methodological transparency notes outlining limitations such as variability in regional reporting and the evolving nature of clinical evidence. These steps were undertaken to produce a defensible, actionable synthesis that supports strategic planning without relying on proprietary market estimates or forecasts.

Concluding synthesis emphasizing the imperative to align clinical innovation, operational readiness, and reimbursement strategies to secure sustained commercialization success

The cumulative findings underscore that gastric space-occupying devices are at an inflection point where engineering innovation, changing care delivery models, and payer expectations converge to create both opportunity and complexity. Devices that deliver adjustable control, simplified delivery, and clear safety profiles align most closely with clinician and patient preferences, while routes of administration that reduce procedural burden expand the addressable patient population. At the same time, regional regulatory diversity and tariff-driven supply chain pressures require deliberate strategic planning to avoid executional missteps.

Navigating this landscape successfully will depend on integrating evidence generation with product roadmaps, aligning distribution strategies to target end-user needs, and reinforcing supply chain flexibility to respond to policy-induced cost dynamics. Organizations that make early investments in real-world evidence infrastructure, payer engagement, and scalable training models will reduce time-to-adoption and strengthen reimbursement positioning. Conversely, firms that neglect these elements may find that promising technical advantages fail to translate into sustainable market penetration.

In sum, the sector is maturing from proof-of-concept innovation toward commercial-scale deployment, and stakeholders who balance clinical value, operational excellence, and market access readiness will lead the next wave of adoption.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gastric Space-Occupying Device Market, by Product Type

  • 8.1. Adjustable
  • 8.2. Dual Fluid-Gas
  • 8.3. Single Fluid-Filled
  • 8.4. Single Gas-Filled

9. Gastric Space-Occupying Device Market, by Route Of Administration

  • 9.1. Endoscopic
  • 9.2. Swallowable

10. Gastric Space-Occupying Device Market, by Duration Of Placement

  • 10.1. Long-Term
  • 10.2. Short-Term

11. Gastric Space-Occupying Device Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Bariatric Clinics
  • 11.3. Hospitals

12. Gastric Space-Occupying Device Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Distributors

13. Gastric Space-Occupying Device Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Gastric Space-Occupying Device Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Gastric Space-Occupying Device Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Gastric Space-Occupying Device Market

17. China Gastric Space-Occupying Device Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Allurion Technologies, Inc.
  • 18.6. Apollo Endosurgery, Inc.
  • 18.7. BaroNova Therapeutics
  • 18.8. Districlass Medical
  • 18.9. Endalis
  • 18.10. Endogastric Solutions
  • 18.11. Fengh Medical
  • 18.12. G-Surgery
  • 18.13. Helioscopie Medical Implants
  • 18.14. Lexel Medical
  • 18.15. Life Partners Europe
  • 18.16. Medicone
  • 18.17. Medsil
  • 18.18. Obalon Therapeutics, Inc.
  • 18.19. Phagia Technologies
  • 18.20. ReShape Lifesciences Inc.
  • 18.21. Silimed
  • 18.22. Silimed Ltda
  • 18.23. Spatz Medical Ltd.
  • 18.24. Tulip Medical

LIST OF FIGURES

  • FIGURE 1. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ADJUSTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ADJUSTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ADJUSTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DUAL FLUID-GAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DUAL FLUID-GAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DUAL FLUID-GAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY SINGLE FLUID-FILLED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY SINGLE FLUID-FILLED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY SINGLE FLUID-FILLED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY SINGLE GAS-FILLED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY SINGLE GAS-FILLED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY SINGLE GAS-FILLED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ENDOSCOPIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ENDOSCOPIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ENDOSCOPIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY SWALLOWABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY SWALLOWABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY SWALLOWABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY LONG-TERM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY LONG-TERM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY LONG-TERM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY SHORT-TERM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY SHORT-TERM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY SHORT-TERM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY BARIATRIC CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY BARIATRIC CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY BARIATRIC CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. GCC GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GCC GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. GCC GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. GCC GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 106. GCC GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GCC GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. G7 GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. G7 GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. G7 GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. G7 GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 124. G7 GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. G7 GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. NATO GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. NATO GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. NATO GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. NATO GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 130. NATO GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. NATO GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DURATION OF PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA GASTRIC SPACE-OCCUPYING DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)